Taking people in BulgariaPhase 3
Continued access to povorcitinib for people with hidradenitis suppurativa from earlier studies
Continues povorcitinib for adults with hidradenitis suppurativa who took part in earlier studies.
Key facts
- Who runs it
- Incyte Corporation
- Where
- Dupnitsa, Lovech, Pleven, Plovdiv, Sevlievo, Sofia, Sofiya, and Stara Zagora, BulgariaSee the 12 sitesAlso in 20 other countries, 295 sites
- Trial code
- Registry title
- Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 600 people, planned
- Started
- 28 Feb 2025
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional
- Treatments tested
- povorcitinib
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who finished treatment in an earlier Incyte trial of povorcitinib and were helped by it. They will keep taking povorcitinib.
- Age
- 18 Years and older
- Sex
- All sexes can join.
- Disease stage
- People who took part in an earlier povorcitinib trial for hidradenitis suppurativa, prurigo nodularis or vitiligo.
- Earlier treatment
- Must have completed the treatment period of an earlier Incyte povorcitinib trial without safety or tolerability problems, and had benefit from the drug, as judged by the study doctor. Cannot join after a biologic immunomodulator (such as adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab) or a live, attenuated vaccine within the 28 days before starting.
Main reasons for not taking part
- Povorcitinib was stopped for good during the earlier trial.
- Povorcitinib was paused for safety or efficacy reasons at or after the last visit of the earlier trial.
- Plans to get a live, attenuated vaccine during the study or within 8 weeks after the last dose.
- Pregnant, planning pregnancy, or breastfeeding.
- Known allergy or severe reaction to povorcitinib, its ingredients, or similar drugs.
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Ability to comprehend and willingness to sign a written ICF for the study
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements
- Willingness to avoid pregnancy or fathering children as defined in the protocol
- Willingness and ability to comply with the study Protocol and procedures
Who cannot take part
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply
- Had been permanently discontinued from study treatment during the parent study
- Women who are pregnant (or who are considering pregnancy) or breastfeeding
Where in Bulgaria
Also in 20 other countries, 295 sites
- Asclepius Medical Center OODDupnitsa, BulgariaTaking people
- Medical Center Medconsult Pleven OODLovech, BulgariaTaking people
- Medical Center Medconsult Pleven OODPleven, BulgariaTaking people
- Diagnostics And Consultancy Center Pulmed EOODPlovdiv, BulgariaTaking people
- UNIMED Medical Center EOODSevlievo, BulgariaTaking people
- Diagnostic And Consulting Center XXVIII-Sofia EOODSofia, BulgariaTaking people
- Diagnostic Consultative Centre Ascendent EOODSofia, BulgariaTaking people
- ASMC IPSMC Skin And Venereal DiseasesSofiya, BulgariaTaking people
- Diagnostic-Consultative Center Alexandrovska EOODSofiya, BulgariaTaking people
- Dkc Fokus-5 Lzip OODSofiya, BulgariaTaking people
- Medical Center Hera EOODSofiya, BulgariaTaking people
- Umbal - Prof. D-R Stoyan Kirkovich ADStara Zagora, BulgariaTaking people
About the trial
What the trial wants to find out
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
The group in the trial
- povorcitinibTreatment being tested
Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Plain-language title
- Continued access to povorcitinib for people with hidradenitis suppurativa from earlier studiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 November 2026